

Buparvaquone

Catalog No: tcsc3254



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:
88426-33-9

Formula:
 $C_{21}H_{26}O_3$

Pathway:
Anti-infection

Target:
Parasite

Purity / Grade:
>98%

Solubility:
DMSO : 33.33 mg/mL (102.10 mM; Need ultrasonic)

Observed Molecular Weight:
326.43


Product Description

Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone.

In Vitro: In 4-day proliferation assays, buparvaquone efficiently inhibits *N. caninum* tachyzoite replication ($IC_{50}=4.9$ nM; $IC_{100}=100$ nM).

nM)^[1]. Buparvaquone is significantly selective against *L. (L.) infantum chagasi* intracellular amastigotes, with an IC_{50} value of 1.5 μ M. Other cutaneous species are also susceptible to buparvaquone, with IC_{50} values in the range 1-4 μ M^[2].

In Vivo: Treatment of *N. caninum* infected mice with buparvaquone (100 mg/kg) either by intraperitoneal injection or gavage prevents neosporosis symptoms in 4 out of 6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treatment^[1]. Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduce cutaneous parasite burden and lesion size, compared with the untreated control^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!